Exploring targeted therapies against RFPL3 for non-small cell lung cancer with lymph node metastasis

探索针对RFPL3的靶向疗法治疗伴淋巴结转移的非小细胞肺癌

阅读:1

Abstract

BACKGROUND: Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths worldwide, marked by its aggressive nature and high likelihood of metastasis. The precise function of ret finger protein-like 3 (RFPL3) in NSCLC progression remains incompletely understood. METHODS: This study measured RFPL3 expression in NSCLC by immunohistochemistry, qPCR, and Western blot. RFPL3's effects on proliferation were assessed with CCK-8 and colony formation assays. Transwell and wound-healing assays evaluated its role in invasion, metastasis, and EMT. In vitro and in vivo studies determined RFPL3's mechanisms driving EMT and lymphatic metastasis. RESULTS: RFPL3 was overexpressed in NSCLC tissues, correlating with lymphatic metastasis and poor prognosis, establishing it as a distinct prognostic risk factor. Knockdown reduced NSCLC cell proliferation, invasion, and metastasis, while overexpression enhanced these malignant phenotypes. RFPL3 increased EMT-related protein expression by western blot, promoting tumor cell metastasis. In vivo, RFPL3 overexpression accelerated tumor growth and lymphatic metastasis in mice. CONCLUSION: This study revealed the critical role of RFPL3 in NSCLC, suggesting that RFPL3 might serve as both a biomarker and a therapeutic target for this type of cancer, which provides new insight for improving patient prognoses.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。